Last reviewed · How we verify
Placebo to match asenapine
Placebo to match asenapine is a Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Control comparator in phase 3 clinical trials of asenapine.
This is an inert placebo formulation designed to match the physical and sensory characteristics of asenapine for blinded clinical trial comparisons.
This is an inert placebo formulation designed to match the physical and sensory characteristics of asenapine for blinded clinical trial comparisons. Used for Control comparator in phase 3 clinical trials of asenapine.
At a glance
| Generic name | Placebo to match asenapine |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Placebos contain no active pharmaceutical ingredient and serve as control comparators in randomized controlled trials. This specific placebo is formulated to match asenapine (an atypical antipsychotic) in appearance, taste, and administration route to maintain blinding in phase 3 trials, allowing researchers to isolate the true therapeutic effect of asenapine from placebo response.
Approved indications
- Control comparator in phase 3 clinical trials of asenapine
Common side effects
Key clinical trials
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) (PHASE3)
- 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124) (PHASE3)
- Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107) (PHASE3)
- A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688) (PHASE3)
- To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770) (PHASE3)
- A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) (PHASE1)
- A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia (PHASE2)
- MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match asenapine CI brief — competitive landscape report
- Placebo to match asenapine updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Placebo to match asenapine
What is Placebo to match asenapine?
How does Placebo to match asenapine work?
What is Placebo to match asenapine used for?
Who makes Placebo to match asenapine?
What development phase is Placebo to match asenapine in?
Related
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Control comparator in phase 3 clinical trials of asenapine
- Compare: Placebo to match asenapine vs similar drugs
- Pricing: Placebo to match asenapine cost, discount & access